Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized multicenter study of suprachoroidal AL-001 in diabetic retinopathy
CTR20261912Phase 2Active
- Sponsor
- Anlong Bio
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of AL001 in diabetic retinopathy (DR), sponsored by Anlong Bio. Started May 2026; status: active.
02
Drugs
AL001
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on CTR20261912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261912.